Monographie - Ganciclovir sodium

Ganciclovir sodium

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Ceptyl	Messico
Ciganclor	Argentina
Citovirax	Italia
Cymevan	Francia
Cymeven	Germania
Cymevene	Australia, Austria, Belgio, Brasile, Chile, Colombia, Croazia, Danimarca, Ecuador, Egitto, Emirati Arabi Uniti, Finlandia, Gran Bretagna, Grecia, Iran, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Messico, Norvegia, Nuova Zelanda, Paesi Bassi, Perù, Polonia, Portogallo, Russo, Spagna, Svezia, Svizzera, Turchia, Ungheria, Venezuela
Cymevir	Brasile
Cytovene	Canada, Stati Uniti d’America
Ganciclovir	Argentina, Canada, Chile, Ecuador, Francia, Germania, Messico, Stati Uniti d’America
Gavir	India
Inglav	Messico
Natclovir	India
Pharcigave	Messico
Umecortil	Colombia, Messico
Viraprex	Messico

Bibliografia : Ganciclovir sodium

	Tipo	Pubblicazione
3	Rivista	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
4	Rivista	Zazempa V, Morgenszejn J, Paul M, Astier A. Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité. Act Pharm Biol Clin 1995 ; 8: 525-528.
36	Rivista	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Rivista	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
67	Rivista	Outman WR, Mitrano FP, Baptista RJ. Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1538-1539.
69	Rivista	Visor GC, Lin LH, Jackson SE, Winterle JS, Lee G, Kenley RA. Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 2810-2812.
70	Rivista	Silvestri AP, Mitrano FP, Baptista RJ, Williams DA. Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Am J Hosp Pharm 1991 ; 48: 2641-2643.
72	Rivista	Johnson CE, Jacobson PA, Chan E. Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1994 ; 51: 503-508.
73	Rivista	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
74	Rivista	Mulye NV, Turco SJ, Speaker TJ. Stability of ganciclovir sodium in an infusion-pump syringe. Am J Hosp Pharm 1994 ; 51: 1348-1349.
76	Rivista	Parasrampuria J, Li LC, Stelmach AH, Sykes TR, Gordon GA. Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. Am J Hosp Pharm 1992 ; 49: 116-118.
81	Rivista	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Rivista	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
88	Rivista	Mole L, Oliva C, O?Hanley P. Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. J Acquired Immune Defic Syndr 1992 ; 5: 354-358.
99	Rivista	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Rivista	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
201	Rivista	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
244	Rivista	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
245	Rivista	Phaypradith S, Vigneron J, Perrin A, Durney-Archeray MJ, Hoffman MA, Hoffman M. Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes. J Pharm Belg 1992 ; 47: 494-498.
248	Rivista	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Rivista	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Rivista	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Rivista	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Rivista	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Rivista	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Rivista	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Rivista	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
479	Rivista	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Rivista	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Rivista	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratorio	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
905	Rivista	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Rivista	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Rivista	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Rivista	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Rivista	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Rivista	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1754	Rivista	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Rivista	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Rivista	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Rivista	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Rivista	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3626	Laboratorio	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3662	Laboratorio	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Rivista	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3796	Rivista	Morlet N, Young S, Naidoo D et al. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. Br Ophtalmol 1995 ; 79: 753-755.
3883	Laboratorio	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4021	Rivista	Guichard N, Bonnabry P, Rudaz S, Fleury S. Long-term stability of ganciclovir in polypropylene containers at room temperature. J Oncol Pharm Practice 2017 ;25,2: 303-308
4521	Rivista	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020